Drug intelligence / Profile preview

Kv1.3 blocker

Development stage: Preclinical
Lead developer: Muna Therapeutics
Modality: Small Molecules
Administration: Intraperitoneal

Overview

Muna Therapeutics is developing an undisclosed small molecule blocker of the Kv1.3 potassium channel for the treatment of neurodegenerative and neuroinflammatory disorders, specifically Parkinson's disease and Multiple Sclerosis. Kv1.3 (encoded by the KCNA3 gene) is a voltage-gated potassium channel that is highly expressed on effector memory T cells and pro-inflammatory (M1-like) microglia. By inhibiting this channel, the drug aims to modulate the immune response and suppress the chronic neuroinflammation that contributes to neuronal loss in Parkinson's disease and demyelination in Multiple Sclerosis. The program is currently in the preclinical stage of development.

Other names: Kv1.3 Blocker (undisclosed name)MUNEY-Kv1.3-small molecule-Parkinson's disease-Multiple Sclerosis

Targets

KCNA3 (Potassium voltage-gated channel subfamily A member 3)

Beyond the preview

Go deeper on Kv1.3 blocker.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kv1.3 blocker.

Explore the full profile